Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes
Kenna Shaw , Russell Broaddus , Mark J. Routbort , Yusha Liu
Clinical Cancer Research 24 ( 5) 1062 -1072
237
2017
Circulating tumor cell-free DNA correlates with the total tumor volume and survival in patients with advanced cancers
S Ahmed , N Elshafeey , HJ Huang , K Madwani
EUROPEAN JOURNAL OF CANCER 103 E57 -E58
2018
Outcomes and after Hyperfractionated, Accelerated Reirradiation for Recurrent Anal Squamous Cell Carcinoma
J McDonald , E Chang , EP Damron , P Das
International Journal of Radiation Oncology, Biology, Physics 117 ( 2) e324 -e324
2023
Salvage Abdominoperineal Resection for Locally Recurrent or Persistent Anal Squamous Cell Carcinoma after Definitive Chemoradiation
EP Damron , J McDonald , P Das , EJ Koay
International Journal of Radiation Oncology, Biology, Physics 117 ( 2) e292 -e292
2023
Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)
J Bendell , GS Eckhardt , HS Hochster , VK Morris
European Journal of Cancer 69
19
2016
MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction
F Janku , HJ Huang , T Fujii , DN Shelton
Annals of Oncology 28 ( 3) 642 -650
46
2017
Sexual Orientation and Gender Identity (SOGI) Data Collection: Opportunities to Advance Best Clinical Practices for LGBTQ+ Patients in Radiation Oncology
BR Schrank , CM Gallagher , L Nguyen , VK Morris
International Journal of Radiation Oncology, Biology, Physics 117 ( 2) e56 -e56
2023
Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 2016; 6: 1352–1365. doi: 10.1158/2159-8290
DS Hong , VK Morris , B El Osta , AV Sorokin
DOI: https://doi. org/10.1158/2159-8290. CD-16-0050. PMID: https://www. ncbi. nlm. nih. gov/pubmed/27729313 1352 -1365
40
Treatment of Metastatic Colorectal Cancer
ASCO Guideline , VK Morris
Observations on the distribution of Salmonella in commercially-produced turkeys during the rearing and fattening stages of production
VK Morris , JJ Carrique-Mas , D Mueller-Doblies , RH Davies
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer
Scott Kopetz , Van K Morris , Nila Parikh , Michael J Overman
BMC Cancer 14 ( 1) 660 -660
11
2014
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
Van K Morris , Mohamed E Salem , Halla Nimeiri , Syma Iqbal
The Lancet Oncology 18 ( 4) 446 -453
163
2017
Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.
Michael S Lee , Elizabeth J McGuffey , Jeffrey S Morris , Ganiraju Manyam
British Journal of Cancer 114 ( 12) 1352 -1361
52
2016
Don’t blame the messenger: Lessons learned for cancer mRNA vaccines during the COVID-19 pandemic
Van K Morris , Scott Kopetz
Nature Reviews Cancer 22 ( 6) 317 -318
3
2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Benny Johnson , Cara L Haymaker , Edwin R Parra , Luisa Maren Solis Soto
Journal for immunotherapy of cancer 10 ( 8)
6
2022
NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.
Van K Morris , Greg Yothers , Scott Kopetz , Samuel A Jacobs
Journal of Clinical Oncology 38
2020
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).
Van K Morris , Greg Yothers , Scott Kopetz , Samuel A Jacobs
Journal of Clinical Oncology 38
2020
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
Van K Morris , Greg Yothers , Scott Kopetz , Samuel A Jacobs
Journal of Clinical Oncology 39 ( 3_suppl) TPS148 -TPS148
5
2021
Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.
Van K Morris , Greg Yothers , Scott Kopetz , Shannon L Puhalla
Journal of Clinical Oncology 42 ( 3_suppl) 5 -5
3
2024
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
Van K Morris , Greg Yothers , Scott Kopetz , Samuel A Jacobs
Journal of Clinical Oncology 40 ( 4_suppl) TPS233 -TPS233
3
2022